~ Buy the VEOZAH (fezolinetant) Drug Profile, 2024 PDF Report in the Report Store ~

VEOZAH Drug Patent Profile

✉ Email this page to a colleague

When do Veozah patents expire, and what generic alternatives are available?

Veozah is a drug marketed by Astellas and is included in one NDA. There are four patents protecting this drug.

This drug has sixty patent family members in twenty-six countries.

The generic ingredient in VEOZAH is fezolinetant. One supplier is listed for this compound. Additional details are available on the fezolinetant profile page.

DrugPatentWatch^® Generic Entry Outlook for Veozah

Veozah will be eligible for patent challenges on May 12, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 12, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Try a Trial

Summary for VEOZAH

International Patents:	60
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for VEOZAH
What excipients (inactive ingredients) are in VEOZAH?	VEOZAH excipients list
DailyMed Link:	VEOZAH at DailyMed

Drug patent expirations by year for VEOZAH

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VEOZAH

Generic Entry Date for VEOZAH^: ⤷ Try a Trial* Constraining patent/regulatory exclusivity: NEW CHEMICAL ENTITY NDA: 216578 Dosage: TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for VEOZAH

G02CX	Other gynecologicals
G02C	OTHER GYNECOLOGICALS
G02	OTHER GYNECOLOGICALS
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for VEOZAH

VEOZAH is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VEOZAH is ⤷ Try a Trial.

This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VEOZAH

N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE WITH MENOPAUSE

NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF MODERATE TO SEVERE VASOMETER SYMPTOMS DUE TO MENOPAUSE

FDA Regulatory Exclusivity protecting VEOZAH

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial		Y		⤷ Try a Trial
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for VEOZAH

See the table below for patents covering VEOZAH around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Norway	2948455		⤷ Try a Trial
Singapore	11201508005X	NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS	⤷ Try a Trial
Croatia	P20171688		⤷ Try a Trial
Japan	2018118988	選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法 (N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS)	⤷ Try a Trial
Lithuania	2552920		⤷ Try a Trial
World Intellectual Property Organization (WIPO)	2011121137		⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration